ORLANDO, Fla. (Ivanhoe Newswire) - Speeding the development and availability of drugs that treat serious diseases are in everyone's interest, especially when the drugs are the first available treatment. The FDA developed a distinct approach to make sure these drugs are available as soon as possible, called fast track.
Researchers are on the fast track to develop a drug that could reverse fibrosis and cirrhosis in the kidneys, lungs, and liver of patients who have NASH—non-alcoholic steatohepatitis—more commonly known as fatty liver disease.
Researchers say that currently there is not a FDA approved drug for fibrosis, so the potential is huge.
NASH affects between nine to 15 million Americans. Over time, patients can develop fibrosis and about three million will develop cirrhosis. The phase 1 clinical trial will enroll patients at six clinical sites in the U.S.
Another potential breakthrough receiving fast track status is a treatment to improve overall survival in patients with metastatic non-small cell lung adenocarcinoma, who have progressed following one chemotherapy regimen. Submit
The drug would be administered in combination with docetaxel. Lung cancer is the leading cause of cancer-related deaths in the world. Non-small cell adenocarcinoma accounts for 40 percent of all lung cancers. It is being evaluated in over 20 clinical trials.
By the way, in 2012 the FDA granted fast track status to 22 drugs. To learn more about the program, go to http://on.nc5.co/1d3aUxo.
BACKGROUND:Fast track is a new process that is created to speed the course of drug review. This was designed so patients with serious illness can receive their drugs at a quicker rate. This process will help patients who are in need of their medications to survive or to function. Heart failure, AIDS, cancer and Alzheimer's are all diseases that Fast Track will work with because it is imperative that these patients receive their medication and treatment. Other illnesses and conditions are considered for the process as well, like diabetes, epilepsy and depression. This process must be requested by the drug company and approved by the FDA before medication is administered, but this will cut the wait time for prescription drugs and keep patients more comfortable and satisfied. (Source:http://www.fda.gov/forconsumers/byaudience/forpatientadvocates/speedingaccesstoimportantnewtherapies/ucm128291.htm)
NONALCOHOLIC STEATOHEPATITIS:Galectin Therapeutics was recently approved by the FDA to release GR-MD-02 to Fast Track. GR-MD-02 is a complex carbohydrate drug that focuses on the galectin-3 protein to reverse liver, kidney and lung cirrhosis. This drug is targeted towards patients who suffer from NASH, nonalcoholic steatohepatitis with advanced fibrosis. This "silent" liver disease affects two to five percent of Americans and is becoming more common due to the growth in obesity. Gelactin Therapeutics conducted a clinical trial on patients with NASH consisting of four weekly doses of GR-MD-02. Forty volunteers at six different clinical sites in the U.S. participated in the study to measure the tolerability and safety of the product. Below is a list of locations:
The Mount Sinai Medical Center (Division of Liver Diseases)
Emory University Hospital (Transplant Center Clinical Research)
METASTATIC NON-SMALL CELL LUNG ADENOCARCINOMA:Lung cancer is the leading cause of cancer deaths in the U.S. in both men and women. However, it is one of the most preventable cancers if detected in early stages. Synta Pharmaceuticals released a drug to stop cancer cell processes. Synta held more than 20 clinical trials with over 700 patients for the product to evaluate the effects on patients. The clinical trial is still ongoing, but is not recruiting volunteers. Here are the locations:
Tuesday, December 10 2013 5:15 PM EST2013-12-10 22:15:07 GMT
Once its spread, melanoma is extremely difficult to treat. Now, researchers say a new therapy is helping them shock away some of the most stubborn tumors.more>>
Each year, more than 76,000 Americans are diagnosed with melanoma, and 9,000 die. Once its spread, this cancer is extremely difficult to treat. Now, researchers say a new therapy is helping them shock away some of the most stubborn tumors.more>>
Wednesday, December 4 2013 5:15 PM EST2013-12-04 22:15:09 GMT
Constant diarrhea, abdominal pain, and intestinal bleeding are just some of the symptoms inflammatory bowel disease patients endure. Now, there's a new therapy for people who have tried everything.more>>
One point four million Americans suffer from inflammatory bowel diseases –like Crohn's and ulcerative colitis. Constant diarrhea, abdominal pain, and intestinal bleeding are just some of the symptoms these patients endure. Now, there's a new therapy for people who have tried everything.more>>
Monday, December 2 2013 5:15 PM EST2013-12-02 22:15:04 GMT
Nearly a million children a year injure their eyes and half of those injuries happen in the home. The younger a child is fitted with a new eye the better.more>>
Nearly a million children a year injure their eyes and half of those injuries happen in the home. Scissors, running with pencils, throwing rocks, sharp corners, and power tools are all to blame. The younger a child is fitted with a new eye the better.more>>
Friday, November 22 2013 5:15 PM EST2013-11-22 22:15:07 GMT
You may think you can avoid them, but in reality most of the foods on your supermarkets shelves contain at least one GMO. When it comes to the GMO debate, things are moving too fast for people to digest.more>>
You may think you can avoid them, but in reality most of the foods on your supermarkets shelves contain at least one GMO. Are they safe? Should you take genetically modified foods off your menu? When it comes to the GMO debate, things are moving too fast for people to digest.more>>